55 In regard to their safety profile, small molecule GLP-1 RAs have also shown similar side effects, being the gastrointestinal symptoms such as nausea, vomiting, and diarrhea the most commonly presented
This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone
The actual clinical evidence for resM specifically is still developing, with a randomized, placebo-controlled trial currently in progress at ClinicalTrials.gov
These examples show how syringe units may change depending on the concentration
TRIUMPH-5 is the closest active-comparator trial
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits